Three of the world’s leading key opinion
leaders (KOL) in neuroscience and schizophrenia to review and
present findings on Newron’s evenamide program for
treatment-resistant schizophrenia
The company will host a Live-Webcast of the
event, beginning at 9:00 AM EDT (2:00 PM GMT, 3:00 PM CEST)
Newron Pharmaceuticals S.p.A. (Newron) (SIX: NWRN, XETRA: NP5),
a biopharmaceutical company focused on the development of novel
therapies for patients with diseases of the central and peripheral
nervous system (CNS), today announced that it will host its 2024
Investor Day on Tuesday, June 25, 2024, at Convene, 530 Fifth
Avenue (between 44th and 45th Streets) in New York City, from
9:00-11:00 AM EDT.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20240618552707/en/
This comprehensive research and investor update event will focus
on Newron’s clinical, scientific and commercial plans for evenamide
for chronic and treatment-resistant schizophrenia.
Three of the leading KOLs in neuroscience and schizophrenia will
review Newron’s Phase III evenamide program and explore the unmet
needs, new concepts and recent neurobiological findings for
treating poor responders and patients with treatment-resistant
schizophrenia (TRS).
These leading experts in psychiatry and schizophrenia are:
Anthony Grace, Ph.D., is
Editor-in-Chief, International Journal of Neuropsychopharmacology,
Distinguished Professor of Neuroscience, and Professor of
Psychiatry and Psychology at the University of Pittsburgh. Dr.
Grace will present breakthrough pre-clinical data on
treatment-resistant schizophrenia: Evenamide can exert unique
efficacy in schizophrenia by targeting the site of pathology:
preclinical evidence supports effects seen in patients with
TRS
John Kane, M.D., Co-Director &
Professor, Institute of Behavioural Science, Feinstein Institutes
for Medical Research, and Professor of Psychiatry, Donald and
Barbara Zucker School of Medicine at Hofstra/Northwell. One of the
leading researchers in the field of schizophrenia, Dr. Kane will
address the topic: Difficult to treat, poorly responding
patients with schizophrenia; new, unique results with evenamide
offer new hope for these patients
Stephen R. Marder, M.D., Daniel X.
Freedman Professor of Psychiatry at the Semel Institute of
Neuroscience & Human Behavior at UCLA and the Director of the
Section on Psychosis at the UCLA Neuropsychiatric Institute. Dr.
Marder's research has focused on the treatment of schizophrenia and
the pharmacology of antipsychotic drugs and he will present: New
Hope for Patients with Treatment-Resistant Schizophrenia; Unique
Results with Evenamide, a Glutamate Modulator, as an Add-On
Medication
Stefan Weber, Chief Executive Officer and Ravi Anand, M.D.,
Chief Medical Officer of Newron will host the event, and will also
present updates on evenamide’s clinical and registration
program.
The event will be held at Convene, 530 Fifth Avenue (between
44th and 45th Streets) in New York City, from 9:00 - 11:00 AM EDT.
Institutional investors, business partners, analysts and media
representatives who are interested in attending in person, or
virtually, must pre-register here
(https://event.webcasts.com/starthere.jsp?ei=1674805&tp_key=06b6bdbd3e).
For any additional information, please email
newron@lavoiehealthscience.com.
International telephone access to the Investor Day conference is
also available at the following numbers:
Switzerland/Europe: +41 (0)800 835 525 United
Kingdom: +44 (0)800 756 3429 Japan: +81 00 531 161 384 United
States: +1 (877) 407 8029
To ensure a timely connection, users are recommended to dial in
at least 10 minutes prior to the scheduled conference. The webcast
will be archived on the Company’s website for one month after the
date of the event.
About evenamide
Evenamide, an orally available new chemical entity, specifically
blocks voltage-gated sodium channels (VGSCs) and is devoid of
biological activity at >130 other CNS targets. It normalizes
glutamate release induced by aberrant sodium channel activity
(veratridine-stimulated), without affecting basal glutamate levels,
due to inhibition of VGSCs. Combinations of ineffective doses of
evenamide and other APs, including clozapine, were associated with
benefit in animal models of psychosis, suggesting synergies in
mechanisms that may provide benefit in patients who are poor
responders to current APs, including clozapine.
About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company
focused on the development of novel therapies for patients with
diseases of the central and peripheral nervous system. The Company
is headquartered in Bresso near Milan, Italy. Xadago®/safinamide
has received marketing authorization for the treatment of
Parkinson’s disease in the European Union, Switzerland, the UK, the
USA, Australia, Canada, Latin America, Israel, the United Arab
Emirates, Japan and South Korea, and is commercialized by Newron’s
Partner Zambon. Supernus Pharmaceuticals holds the
commercialization rights in the USA. Meiji Seika has the rights to
develop and commercialize the compound in Japan and other key Asian
territories. Newron is also developing evenamide as the potential
first add-on therapy for the treatment of patients with symptoms of
schizophrenia. For more information, please visit:
www.newron.com
Important Notices
This document contains forward-looking statements, including
(without limitation) about (1) Newron’s ability to develop and
expand its business, successfully complete development of its
current product candidates, the timing of commencement of various
clinical trials and receipt of data and current and future
collaborations for the development and commercialization of its
product candidates, (2) the market for drugs to treat CNS diseases
and pain conditions, (3) Newron’s financial resources, and (4)
assumptions underlying any such statements. In some cases, these
statements and assumptions can be identified by the fact that they
use words such as “will”, “anticipate”, “estimate”, “expect”,
“project”, “intend”, “plan”, “believe”, “target”, and other words
and terms of similar meaning. All statements, other than historical
facts, contained herein regarding Newron's strategy, goals, plans,
future financial position, projected revenues and costs and
prospects are forward-looking statements. By their very nature,
such statements and assumptions involve inherent risks and
uncertainties, both general and specific, and risks exist that
predictions, forecasts, projections and other outcomes described,
assumed or implied therein will not be achieved. Future events and
actual results could differ materially from those set out in,
contemplated by or underlying the forward-looking statements due to
a number of important factors. These factors include (without
limitation) (1) uncertainties in the discovery, development or
marketing of products, including without limitation difficulties in
enrolling clinical trials, negative results of clinical trials or
research projects or unexpected side effects, (2) delay or
inability in obtaining regulatory approvals or bringing products to
market, (3) future market acceptance of products, (4) loss of or
inability to obtain adequate protection for intellectual property
rights, (5) inability to raise additional funds, (6) success of
existing and entry into future collaborations and licensing
agreements, (7) litigation, (8) loss of key executive or other
employees, (9) adverse publicity and news coverage, and (10)
competition, regulatory, legislative and judicial developments or
changes in market and/or overall economic conditions. Newron may
not actually achieve the plans, intentions or expectations
disclosed in forward-looking statements and assumptions underlying
any such statements may prove wrong. Investors should therefore not
place undue reliance on them. There can be no assurance that actual
results of Newron's research programs, development activities,
commercialization plans, collaborations and operations will not
differ materially from the expectations set out in such
forward-looking statements or underlying assumptions. Newron does
not undertake any obligation to publicly update or revise
forward-looking statements except as may be required by applicable
regulations of the SIX Swiss Exchange or the Dusseldorf Stock
Exchange where the shares of Newron are listed. This document does
not contain or constitute an offer or invitation to purchase or
subscribe for any securities of Newron and no part of it shall form
the basis of or be relied upon in connection with any contract or
commitment whatsoever.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240618552707/en/
For more information, please contact: Newron
Stefan Weber CEO +39 02 6103 46 26 pr@newron.com UK/Europe
Simon Conway / Ciara Martin / Natalie Garland-Collins FTI
Consulting +44 20 3727 1000 SCnewron@fticonsulting.com
Switzerland Valentin Handschin IRF +41 43 244 81 54
handschin@irf-reputation.ch Germany/Europe Anne Hennecke /
Caroline Bergmann MC Services +49 211 52925222
newron@mc-services.eu USA Paul Sagan LaVoieHealthScience +1
617 374 8800, Ext. 112 psagan@lavoiehealthscience.com